On Wednesday, RBC Capital analysts reiterated their Sector Perform rating on Design Therapeutics Inc (NASDAQ: DSGN) stock, maintaining a price target of $5.00, representing a 25% upside from the ...

U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4 ...

Akash Vatsa, who was onboard the Boeing 787 Dreamliner that crashed, killing more than 260 people, was on its earlier leg from Delhi to Ahmedabad. | Latest News India ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (dela ...

The International Volcanic Health Hazard Network has outlined the potential health risks from today's incident on the coast of Sicily ...

Mount Etna on the coast of Sicily has experienced a dramatic eruption today. The incident saw smoke belch into the sky as onlookers fled. The so-called Strombolian eruption led to a moderate ...

Bozorgmehr Pouyeh; Anat Galor; Darlene Miller; Eduardo C Alfonso. Disclosures. Expert Rev Ophthalmol. 2011;6(5):529-540.

Mount Etna erupted on the Italian island of Sicily this morning, prompting a 'red alert' warning, with dramatic video showing tourists running down the mountain ...

Andy Fletcher, chief executive of charity Muscular Dystrophy UK, said the decision not to approve the drug for NHS use "sends a disheartening message to those affected by rare and complex conditions".

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.

Case Presentation A 36 year - old man with Fuchs' dystrophy underwent combined phacoemulsification and DSAEK of the right eye. Immediately postoperatively, ...

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD), setting it on course to become the first non-steroidal ...